13th Annual Biotech and Specialty Pharmaceuticals Conference
The biotech sector has rebounded off its Q1 lows of the year, but
does the industry have what it takes to survive the long term? The major
biotech indexes are either matching or outperforming the S&P 500. At
the beginning of October, the Nasdaq Biotech Stock Index (NBI) was up
nearly 10% YTD and the AMEX Biotech Index (BTK) had gains of almost 40%.
The S&P 500 was up approximately 10%.
Despite the ripple effects of the credit crisis and the uncertainty
of the global economy, many analysts expect the biotech sector to
outperform by the end of 2009 and throughout 2010. Increasing
M&A activity is expected into next year, serving as the biggest
driver behind sector gains. Larger companies seeking bigger pipelines
will continue to look for deals as smaller biotech companies face a cash
crunch.
However, experts say that while the fundamentals behind biotech and
specialty pharmaceuticals’ growth —an aging population and
the ever-growing demand for healthcare—remain, investors are now
looking at companies’ cash positions more than ever before. This
is particularly true in the case of small- and micro-caps, where cash on
hand and ability to access capital are most critical to survival.
Don’t miss this chance to learn about opportunities in
investing in specialty pharmaceutical and biotechnology companies. The
CEOs, CFOs, and other executives from some of the industry’s most
innovative small- and micro-cap companies will discuss their plans to
invent, develop, research, and market important new drugs, diagnostics,
and delivery technologies.
|
DATE:
Tuesday, December 1, 2009
TIME:
8:30 a.m.–3:15 p.m.
LOCATION:
NYSSA
1177 Avenue of the Americas, 2nd Floor
(between 45th and 46th Streets), NYC (Directions)
Photo ID required for access to the building.
|
REGISTRATION/FEES:
Early Registration by November 17
$195 Members | $295 Nonmembers
Regular Registration between November 18–24
$265 Members | $365 Nonmembers
Late Registration after November 25
$315 Members | $415 Nonmembers
Register at the door: Additional $50 due (space permitting)
CREDIT: 1 CE/CPE
|
If you would like to media partner or sponsor any of these
programs, please contact sponsorship@nyssa.org.
Agenda
| 8:30 |
Check-in and Continental
Breakfast |
| 8:55 |
Welcome and Opening Remarks |
| 9:00 |
Outlook for the Biotech and Specialty
Pharmaceuticals Industry
George Fulop, MD, Managing Director, Stuyvesant Capital
Management |
| 9:40 |
Inovio Biomedical Corporation (NYSE, AMEX:
INO)
J. Joseph Kim, President & CEO
Inovio Biomedical is focused on the design, development, and delivery of
a new generation of vaccines, called DNA vaccines, to prevent and treat
cancers and infectious diseases. |
| 10:15 |
Break |
| 10:30 |
Cyclacel Pharmaceuticals, Inc. (Nasdaq:
CYCC)
Spiro Rombotis, President and CEO
Cyclacel is a development-stage biopharmaceutical company dedicated to
the discovery, development and commercialization of novel,
mechanism-targeted drugs to treat human cancers and other serious
disorders. |
| 11:05 |
GenSpera, Inc. (OTCBB: GNSZ)
Craig A, Dionne, PhD, President and CEO
GenSpera develops potent anti-cancer drugs that are activated only
within the tumor. |
| 11:40 |
Emisphere Technologies (EMIS)
Michael Novinski, President and CEO
Emisphere is charting new frontiers in drug delivery. Emisphere’s
core business strategy is to use its proprietary Eligen® Technology
to develop novel oral forms of injectable drugs or poorly absorbed
compounds. |
| 12:15 |
Lunch |
| 12:40 |
Luncheon Presentation: Mergers and Acquisitions
in the Biotech Industry
Damien Conover, CFA, Senior Equity Analyst, Equities
Strategist, Editor of Morningstar Healthcare Observer, Morningstar,
Inc.
As big pharma approaches its patent cliff, biotechnology firms offer a
source of potential growth: A look at the most likely biotech
takeout targets using Morningstar’s propriety ranking system. |
| 1:30 |
DARA BioSciences, Inc. (Nasdaq: DARA)
Richard A. Franco, President, CEO and Chairman
DARA is a biopharmaceutical company developing small molecules through
human proof-of-concept for ultimate monetization to large pharma. |
| 2:05 |
Echo Therapeutics (OTCBB: ECTE)
Patrick Mooney, Chairman & CEO
Echo Therapeutics is developing the Symphony tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system
for patients with diabetes and for use in hospital critical care units.
Echo is also developing its needle-free Prelude SkinPrep System for
transdermal drug delivery of a wide range of novel topical
reformulations of widely-used, FDA-approved products. |
| 2:40 |
Provectus Pharmaceuticals, Inc (OTCBB:
PVCT)
Timothy C. Scott, PhD., President
Provectus Pharmaceuticals specializes in developing oncology and
dermatology therapies, with its lead oncology agent, PV-10. |
| 3:15 |
Closing Remarks and Adjournment |
| |
|
|
